Multi‐Omics Biomarkers for Predicting Efficacy of Biologic and Small‐Molecule Therapies in Adults With Inflammatory Bowel Disease: A Systematic Review
United European Gastroenterology Journal · 2025-05 · 13 (4) · 517-530
DOI: 10.1002/ueg2.12720 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift United European Gastroenterology Journal, online erschienen am 10.12.2024. Verfasst von Liru Chen und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China. Hauptthemen laut MEDLINE: Biological Products, Inflammatory Bowel Diseases. Die Arbeit wurde bisher 38-mal zitiert (Crossref) und nennt 92 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Guangxi Zhuang Autonomous Region, National Key Research and Development Program of China.
Abstract (Originalsprache)
The heterogeneity and suboptimal efficacy of biological treatments and small molecule drugs necessitate their precise selection based on biomarkers that predict therapeutic responses in inflammatory bowel disease. Recent studies have identified numerous novel biomarkers predictive of responses to biologics and small molecule modulators, utilizing a variety of omics approaches in inflammatory bowel disease. In this review, we systematically examine baseline omics biomarkers that predict responses to biological therapies and small molecule drugs, drawing on literature from PubMed. Our analysis spans multiple omics disciplines, including genomics, transcriptomics (both bulk RNA and single‐cell RNA sequencing), proteomics, microbiomics, and metabolomics, with particular emphasis on the impact of models integrating multiple omics datasets. Additionally, to further the field of precision medicine, we evaluated specific biomarkers that may exhibit distinct effects on responses to multiple therapeutic interventions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
- Institute of Precision Medicine, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
- Guangxi Hospital Division, The First Affiliated Hospital, Sun Yat-sen University, Nanning, China.
ORCID-Profile: Liru Chen, Jinshen He, Zishan Liu, Rui Feng
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Guangxi Zhuang Autonomous Region
- National Key Research and Development Program of China
Zitieren
APA
Chen, L., Zhang, C., Niu, R., Xiong, S., He, J., Wang, Y., Zhang, P., Su, F., Liu, Z., Zhou, L., Mao, R., Hu, S., Chen, M., Qiu, Y., & Feng, R. (2025). Multi‐Omics Biomarkers for Predicting Efficacy of Biologic and Small‐Molecule Therapies in Adults With Inflammatory Bowel Disease: A Systematic Review. United European Gastroenterology Journal, 13(4), 517-530. https://doi.org/10.1002/ueg2.12720
Vancouver
Chen L, Zhang C, Niu R, Xiong S, He J, Wang Y, et al. Multi‐Omics Biomarkers for Predicting Efficacy of Biologic and Small‐Molecule Therapies in Adults With Inflammatory Bowel Disease: A Systematic Review. United European Gastroenterology Journal. 2025;13(4):517-530. doi:10.1002/ueg2.12720
BibTeX
@article{Chen2025,
author = {Chen, Liru and Zhang, Chuhan and Niu, Ruixuan and Xiong, Shanshan and He, Jinshen and Wang, Yu and Zhang, Pingxin and Su, Fengyuan and Liu, Zishan and Zhou, Longyuan and Mao, Ren and Hu, Shixian and Chen, Minhu and Qiu, Yun and Feng, Rui},
title = {Multi‐Omics Biomarkers for Predicting Efficacy of Biologic and Small‐Molecule Therapies in Adults With Inflammatory Bowel Disease: A Systematic Review},
journal = {United European Gastroenterology Journal},
year = {2025},
volume = {13},
number = {4},
pages = {517--530},
doi = {10.1002/ueg2.12720}
}
EUVIMED